The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit cdk5 -mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
本发明提供了与
PPARG(
PPARγ)高亲和力结合,抑制cdk5介导的
PPARG
磷酸化,但不对
PPARG产生激动作用的分子实体。本发明的化合物可用于治疗
PPARG在糖尿病或肥胖症患者中发挥作用的情况。本发明还提供了制备该化合物的方法,评估该化合物作为非激动性
PPARG结合化合物的
生物测定方法以及制药组合物。